About Proteon Therapeutics
Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: PRTO
- CUSIP:
Key Metrics:
- Previous Close: $9.66
- 50 Day Moving Average: $9.17
- 200 Day Moving Average: $7.95
- 52-Week Range: $4.90 - $17.76
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.06
- P/E Growth: 0.00
- Market Cap: $160.18M
- Outstanding Shares: 16,582,000
- Beta: 2.3
Profitability:- Return on Equity: -43.37%
- Return on Assets: -40.72%
Debt:- Current Ratio: 11.61%
- Quick Ratio: 11.61%
Additional Links:
Companies Related to Proteon Therapeutics:
Earnings History for Proteon Therapeutics (NASDAQ:PRTO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/10/2016 | | | | | | | | |
| 8/8/2016 | | ($0.43) | ($0.48) | | | View | N/A |  |
| 5/9/2016 | Q1 | ($0.41) | ($0.40) | | | View | N/A | |
| 3/14/2016 | | ($0.34) | ($0.39) | | | View | N/A | |
| 11/12/2015 | Q315 | ($0.33) | ($0.33) | | | View | N/A | |
| 8/13/2015 | Q215 | ($0.30) | ($0.31) | | | View | N/A | |
| 5/13/2015 | | ($0.24) | ($0.28) | | | View | N/A | |
| 3/20/2015 | | ($0.26) | ($0.24) | | | View | N/A | |
| 11/26/2014 | | ($0.31) | ($31.03) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Proteon Therapeutics (NASDAQ:PRTO)Current Year EPS Consensus Estimate: $-1.86 EPS
Next Year EPS Consensus Estimate: $-1.91 EPS
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2016 | 1 | ($0.42) | ($0.42) | ($0.42) |
| Q2 2016 | 1 | ($0.43) | ($0.43) | ($0.43) |
| Q3 2016 | 1 | ($0.46) | ($0.46) | ($0.46) |
| Q4 2016 | 1 | ($0.50) | ($0.50) | ($0.50) |
(Data provided by Zacks Investment Research)
Dividend History for Proteon Therapeutics (NASDAQ:PRTO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Proteon Therapeutics (NASDAQ:PRTO)Insider Ownership Percentage: 50.90%
Institutional Ownership Percentage: 51.54%
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/6/2016 | George Arthur Eldridge | CFO | Buy | 4,000 | $5.78 | $23,120.00 | |
| 12/1/2015 | Timothy P. Noyes | CEO | Sell | 5,000 | $14.97 | $74,850.00 | |
| 11/2/2015 | Timothy P. Noyes | CEO | Sell | 5,000 | $13.50 | $67,500.00 | |
| 10/1/2015 | Timothy P. Noyes | CEO | Sell | 5,000 | $13.33 | $66,650.00 | |
| 9/8/2015 | Timothy P. Noyes | CEO | Sell | 5,000 | $13.55 | $67,750.00 | |
| 7/7/2015 | Daniel Philip Gottlieb | VP | Sell | 1,965 | $16.86 | $33,129.90 | |
| 10/27/2014 | James E Flynn | Insider | Buy | 691,713 | $10.00 | $6,917,130.00 | |
| 10/27/2014 | Skyline Venture Partners Quali | Major Shareholder | Sell | 56,038 | $10.00 | $560,380.00 | |
| 10/27/2014 | Timothy Haines | Director | Buy | 950,000 | $10.00 | $9,500,000.00 | |
(Data available from 1/1/2013 forward)
Latest Headlines for Proteon Therapeutics (NASDAQ:PRTO)| Date | Headline |
|---|
 | Proteon Therapeutics : to Present at Two Upcoming Investor Conferences (NASDAQ:PRTO)
www.4-traders.com - September 24 at 11:16 AM |
 | Proteon Therapeutics to Present at Two Upcoming Investor Conferences (NASDAQ:PRTO)
www.publicnow.com - September 1 at 10:00 AM |
 | Proteon Therapeutics Announces Second Quarter 2016 Financial Results (NASDAQ:PRTO)
globenewswire.com - August 8 at 7:11 PM |
 | Proteon Therapeutics Inc.: Proteon Therapeutics Announces Second Quarter 2016 Financial Results (NASDAQ:PRTO)
www.twst.com - August 8 at 7:11 PM |
 | Proteon Therapeutics reports 2Q loss (NASDAQ:PRTO)
sg.finance.yahoo.com - August 8 at 11:40 AM |
 | 7 Stocks Under $10 to Trade for Big Post-Brexit Gains (NASDAQ:PRTO)
www.thestreet.com - August 3 at 10:11 AM |
 | Have You Ever Heard Of Proteon Therapeutics? (NASDAQ:PRTO)
seekingalpha.com - July 19 at 7:05 PM |
| Proteon Therapeutics (PRTO) in Focus: Stock Gains 6.4% (NASDAQ:PRTO)
finance.yahoo.com - June 24 at 8:45 AM |
| Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 22nd (NASDAQ:PRTO)
www.publicnow.com - June 15 at 8:29 AM |
| PROTEON THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:PRTO)
biz.yahoo.com - June 13 at 8:01 AM |
 | Proteon Therapeutics, Inc. :PRTO-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 (NASDAQ:PRTO)
www.capitalcube.com - June 8 at 6:07 PM |
| Proteon Therapeutics reports 1Q loss (NASDAQ:PRTO)
sg.finance.yahoo.com - May 9 at 8:28 AM |
| Proteon Therapeutics Announces First Quarter 2016 Financial Results (NASDAQ:PRTO)
www.publicnow.com - May 9 at 8:18 AM |
| PROTEON THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:PRTO)
biz.yahoo.com - May 9 at 8:02 AM |
| Proteon Therapeutics Announces Survey Findings Demonstrating Impact of Vascular Access Failure on Hemodialysis Patients (NASDAQ:PRTO)
www.publicnow.com - April 28 at 7:22 AM |
| Coverage initiated on Proteon Therapeutics by Robert W. Baird (NASDAQ:PRTO)
finance.yahoo.com - April 14 at 5:41 AM |
 | Proteon Therapeutics Reports Publication of Promising Nonclinical Results from Vonapanitase in Peripheral Artery Disease (NASDAQ:PRTO)
feeds.benzinga.com - April 13 at 9:33 AM |
| Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease (NASDAQ:PRTO)
www.publicnow.com - April 13 at 8:24 AM |
| Proteon Therapeutics reports 4Q loss (NASDAQ:PRTO)
sg.finance.yahoo.com - March 14 at 8:57 AM |
| Proteon Therapeutics Announces Fourth Quarter and Full-Year 2015 Financial Results (NASDAQ:PRTO)
finance.yahoo.com - March 14 at 8:30 AM |
| Proteon Therapeutics to Present at the 2016 BIO CEO & Investor Conference February 8th (NASDAQ:PRTO)
finance.yahoo.com - February 2 at 8:00 AM |
| PROTEON THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:PRTO)
biz.yahoo.com - January 22 at 8:31 AM |
| PROTEON THERAPEUTICS INC Financials (NASDAQ:PRTO)
finance.yahoo.com - December 8 at 1:17 PM |
| Proteon Therapeutics to Present at the Oppenheimer 26th Annual Healthcare Conference December 9th (NASDAQ:PRTO)
finance.yahoo.com - December 2 at 8:00 AM |
| Proteon Therapeutics to Present at the Stifel 2015 Healthcare Conference on November 17th (NASDAQ:PRTO)
finance.yahoo.com - November 13 at 7:45 AM |
| PROTEON THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh (NASDAQ:PRTO)
biz.yahoo.com - November 12 at 4:17 PM |
| Proteon Therapeutics reports 3Q loss (NASDAQ:PRTO)
sg.finance.yahoo.com - November 12 at 9:25 AM |
 | Proteon Therapeutics Announces Third Quarter 2015 Financial Results (NASDAQ:PRTO)
www.noodls.com - November 12 at 8:26 AM |
| Proteon Therapeutics to Host Research and Development Day on November 20, 2015 (NASDAQ:PRTO)
finance.yahoo.com - November 9 at 11:58 AM |
| PROTEON THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:PRTO)
biz.yahoo.com - November 2 at 4:17 PM |
| Proteon Therapeutics Completes Enrollment in PATENCY-1, First Phase 3 Clinical Study of Investigational Vonapanitase (NASDAQ:PRTO)
finance.yahoo.com - November 2 at 4:15 PM |
| Proteon Therapeutics to Present at the BIO-Europe 2015 Conference November 3 (NASDAQ:PRTO)
finance.yahoo.com - October 28 at 5:00 PM |
| Proteon Therapeutics Appoints Tony Kingsley to Its Board of Directors (NASDAQ:PRTO)
www.noodls.com - October 19 at 8:31 AM |
| PROTEON THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi (NASDAQ:PRTO)
biz.yahoo.com - October 19 at 8:02 AM |
| Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015 (NASDAQ:PRTO)
www.noodls.com - October 12 at 8:25 AM |
Proteon Therapeutics (NASDAQ:PRTO) Chart for Sunday, September, 25, 2016
